OVERTURE Phase 2 Clinical Trial MRI Outcomes Demonstrate Consistent Treatment Benefits in Subgroup Analysis
Ralph Kern, Colin Kuang, Chandran Seshagiri, Alexandra Konisky, Alyssa Galley, Alyssa Boasso, Evan Hempel, Zach Malchano, Brent Vaughan, Aylin Cimenser, Xiao Da, Monika Shpokayte, Mihaly Hajos · 2025
Read OVERTURE Phase 2 Clinical Trial MRI Outcomes Demonstrate Consistent Treatment Benefits in Subgroup Analysis by Ralph Kern, Colin Kuang, Chandran Seshagiri, Alexandra Konisky, Alyssa Galley, Alyssa Boasso, Evan Hempel, Zach Malchano, Brent Vaughan, Aylin Cimenser, Xiao Da, Monika Shpokayte, Mihaly Hajos (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11714597.txt.
Description
Kern and twelve co-authors report brain imaging results from the OVERTURE trial in Alzheimer's disease, published in two thousand twenty-five. The trial tested a home device that delivers light and sound pulsing at forty hertz for an hour a day, aiming to slow the disease.
Seventy-six patients with mild to moderate Alzheimer's were randomized, with twice as many getting the real stimulation as the sham version, for six months. Brain scans showed the active group lost whole brain volume much more slowly, with about a sixty-nine percent reduction in shrinkage compared with sham. Benefits looked similar across age, disease stage, gene status, and amyloid level subgroups. The results support further testing of this non-drug approach.
Catalog record
| CREATOR | Ralph Kern, Colin Kuang, Chandran Seshagiri, Alexandra Konisky, Alyssa Galley, Alyssa Boasso, Evan Hempel, Zach Malchano, Brent Vaughan, Aylin Cimenser, Xiao Da, Monika Shpokayte, Mihaly Hajos |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |